The promise of proteomics to yield critical disease data has long been known. But, until now, there have been major technical and economic barriers to broad-scale proteomics analyses. A primary obstacle has been the difficulty in managing the huge dynamic range of protein concentrations, with variations of 10-12 orders of magnitude from the most to the least abundant proteins in the plasma and other biologic fluids.
Research approaches have been developed to broadly analyze proteins across this dynamic range, but these approaches can take days to weeks to analyze a single sample. Our proprietary Proteograph technology platform is designed to overcome these challenges and to deliver on the promise of proteomics’ differentiated fundamental insights into disease mechanism and to thereby enable breakthrough applications such as pre-symptomatic detection of cancer, neurological and other diseases.